Home   Chapter Home   Jobs   Conferences   Fellowships   Books



Advertisement

Drugs of interest to pathologists

Drugs related to surgical pathology

Sunitinib malate


Author: Him G. Kwee, M.D. (see Reviewers/Authors page)
Revised: 8 November 2011, last major update October 2011
Copyright: (c) 2011, PathologyOutlines.com, Inc.

General
=========================================================================

● An inhibitor of multiple tyrosine kinase (TK) enzymes such as: KIT (CD 117), PDGFR (platelet-derived growth factor receptors), VEGFR (vascular endothelial growth factor receptors), RET (rearranged during transfection proto-oncogene), CSF-1R (colony stimulating factor 1 receptor ) and flt3 (fms-related tyrosine kinase 3, Wikipedia)

Trade name
=========================================================================

● Sutent

Clinical information
=========================================================================

Approved by US Food and Drug Administration for:
● Gastrointestinal stromal tumor/GIST resistant to imatinib/Gleevec or for GIST patients that cannot tolerate imatinib (Lancet 2006;368:1329), approved January 2006
● Metastatic renal cell carcinoma (approved January 2006)
● Unresectable or metastatic pancreatic neuroendocrine tumor (approved May 2011, Sutent package insert)

● Cost: in 2006, $4480 per 6 weeks cycle or $17,920 per 6 months (National PBM Drug Monograph on Sunitinib)

Use for pathologists
=========================================================================

Imatinib mesylate is approved by US Food and Drug Administration for first line treatment of GIST and sunitinib for second line treatment of GIST
● Both drugs bind to and stabilize the inactivated form of the receptor tyrosine kinases, but they differ in their binding targets as well as inhibitory activity
● Imatinib binds to amino acid residues within the ATP-binding pocket as well as the activation loop, whereas sunitinib interacts with different amino acid residues in the ATP binding pocket
● Sunitinib also posseses activity against VEGFR 1/3 and thus has antiangiogenic properties as well
● Sunitinib can also inhibit KIT-PDGFR wild type GIST including pediatric GIST (Arch Pathol Lab Med 2011;135:1298)

End of Drugs > Drugs related to surgical pathology > Sunitinib malate


This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.

All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).